OrganiGram Holdings Inc. (NASDAQ:OGI) Receives Consensus Rating of “Hold” from Brokerages

OrganiGram Holdings Inc. (NASDAQ:OGIGet Rating) has been given a consensus rating of “Buy” by the nine analysts that are currently covering the company, MarketBeat reports. Four equities research analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $3.36.

A number of equities analysts recently commented on the company. Atb Cap Markets raised OrganiGram from a “sector perform” rating to an “outperform” rating in a report on Tuesday, April 12th. Zacks Investment Research raised OrganiGram from a “sell” rating to a “hold” rating in a report on Wednesday, March 30th.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. PCG Wealth Advisors LLC purchased a new position in OrganiGram in the fourth quarter worth about $25,000. Two Sigma Securities LLC purchased a new position in shares of OrganiGram during the third quarter valued at approximately $35,000. Invesco Ltd. purchased a new position in shares of OrganiGram during the second quarter valued at approximately $51,000. Gotham Asset Management LLC purchased a new position in shares of OrganiGram during the fourth quarter valued at approximately $33,000. Finally, Bridgewater Associates LP purchased a new position in shares of OrganiGram during the fourth quarter valued at approximately $36,000. Institutional investors own 11.78% of the company’s stock.

NASDAQ OGI opened at $1.21 on Friday. The business’s fifty day moving average price is $1.49 and its 200-day moving average price is $1.66. The stock has a market capitalization of $379.56 million, a price-to-earnings ratio of -13.44 and a beta of 0.36. OrganiGram has a 1-year low of $1.10 and a 1-year high of $3.52.

OrganiGram (NASDAQ:OGIGet Rating) last released its quarterly earnings results on Tuesday, April 12th. The company reported ($0.02) earnings per share for the quarter, meeting the consensus estimate of ($0.02). OrganiGram had a negative return on equity of 12.28% and a negative net margin of 32.87%. The firm had revenue of $25.04 million for the quarter, compared to analysts’ expectations of $24.28 million. During the same period in the prior year, the firm earned ($0.09) EPS. As a group, analysts expect that OrganiGram will post -0.11 EPS for the current fiscal year.

OrganiGram Company Profile (Get Rating)

Organigram Holdings Inc, through its subsidiaries, produces and sells cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including cannabis flowers, cannabis oils, and vaporizers for civilian patients and veterans; adult use recreational cannabis under the Edison Cannabis Co, Trail Blazer, SHRED, SHRED'ems, Big Bag O' Buds, and Monjour brands; and cannabis edibles products and concentrates.

Further Reading

Analyst Recommendations for OrganiGram (NASDAQ:OGI)

Receive News & Ratings for OrganiGram Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OrganiGram and related companies with MarketBeat.com's FREE daily email newsletter.